| Original Article |
View full article
July 25, 2016
|Vol. 3, Issue 5|
Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer
Takeshi Kotake, Yuichiro Kikawa, Sachiko Takahara, Shigeru Tsuyuki, Hiroshi Yoshibayashi, Eiji Suzuki, Yoshio Moriguchi, Hiroyasu Yamashiro, Kazuhiko Yamagami, Hirofumi Suwa, Toshitaka Okuno, Takahito Okamura, Takashi Hashimoto, Hironori Kato, Akihito Tsuji and Masakazu Toi
Corresponding author: Takeshi Kotake, Breast Surgery Department, Kyoto University Hospital, 54, Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan
Introduction: A multicenter observational retrospective study was conducted to assess the clinical response and survival impact, especially post-progression survival impact, of eribulin monotherapy in HER2-negative advanced or metastatic breast cancer (A/MBC) patients. Patients and methods: This retrospective observation cohort study contains 110 A/MBC patients treated with eribulin monotherapy during April 2011 and August 2014 in 12 Kyoto Breast Cancer Research Network (KBCRN) institutions.
Citation: Kotake T, Kikawa Y, Takahara S, Tsuyuki S, Yoshibayashi H, et al. (2016) Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer. Int J Cancer Clin Res 3:061.